EUCTR2006-005872-42-GB进行中（未招募）不适用
A Phase II study of MGCD0103 (MG-0103) in patients with acute myelogenous leukemia/high risk MDS who are elderly and have previously untreated disease or who are adult and have relapsed/refractory disease
Pharmion GmbH0 个研究点目标入组 82 人开始时间: 2007年1月14日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 82
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must fulfill all of the following inclusion criteria in order to be admitted into the study:
- •i. Pathologic confirmation of AML or high-risk MDS (bone marrow blast count =10% or presence of peripheral blasts).
- •ii. Prior treatment
- •a. Elderly cohort: no prior chemotherapy treatment for AML/high-risk MDS and are not currently candidates for intensive chemotherapy. Prior treatment with agents such as hydroxyurea or corticosteroids used for peripheral count control will be allowed. Prior treatment for non-high-risk MDS will be allowed.
- •b.Relapsed/refractory cohort: Disease that is relapsed or refractory to prior treatment.
- •a. Elderly cohort: 70 years or greater
- •b.Relapsed/refractory cohort: 18 years or greater
- •iv. ECOG performance status of 0 or 1.
- •v. Laboratory requirements:
- •Total Bilirubin = 1.5 x Upper Limit of Normal (ULN)
- •Aspartate transaminase (AST /SGOT) and alanine transaminase (ALT / SGPT) =2.5 x ULN
- •Serum Creatinine = 1.5 x ULN
- •vi. Patients or their legal representative must be able to read, understand, and sign a
- •written informed consent (approved by the institutional review board/Ethics
- •Committee (IRB/EC)).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients fulfilling any of the following criteria will not be admitted into the study:
- •i. Pregnant or lactating women. Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test documented within 7 days prior start of study drug.
- •ii. WOCBP and men whose partners are WOCBP must use an acceptable method of contraception while enrolled on this study, and for a period of 3 months following study drug treatment. Patients unwilling or unable to follow this guideline will be excluded. An example of an acceptable form of contraception is a double barrier method, such as condom with diaphragm.
- •iii. Patients with uncontrolled intercurrent illness, active or uncontrolled infections, or a fever >38.5°C (not due to tumor fever) on the day of scheduled dosing.
- •iv. Patients with serious illnesses, medical conditions, or other medical history, including laboratory results, which, in the investigator’s opinion, would be likely to interfere with a patient’s participation in the study, or with the interpretation of the results.
- •v. Patients who have been treated with any investigational drug within 30 days prior to study initiation (an investigational drug is one for which there is no approved indication), or who are receiving concurrent treatment with other experimental drugs or anti-cancer therapy.
- •vi. Known hypersensitivity to HDAC inhibitors, to any of the components of MG-0103.
- •vii. Known HIV (human immunodeficiency virus) or known active Hepatitis B or C. Testing is not required for patients not suspected of having these conditions. For patients with a history of Hepatitis B or C that is no longer active, the Investigator should contact MethylGene in advance to confirm patient’s eligibility.
- •viii. Any condition (e.g., known or suspected poor compliance, psychological instability, geographical location, etc) that, in the judgment of the investigator, may affect the patient’s ability to sign the informed consent and undergo study procedures.
- •ix. Any condition that will put the patient at undue risk or discomfort as a result of adherence to study procedures. For example, consider requirement to take MG-0103 with a low-pH drink and recommendation to avoid agents that increase gastric-pH.
研究者
相似试验
已完成
2 期
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic LeukemiaLymphocytic Leukemia, ChronicNCT00431873Mirati Therapeutics Inc.21
已完成
1 期
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous LeukemiaAcute Myelogenous LeukemiaMyelodysplastic SyndromeNCT00324220Mirati Therapeutics Inc.66
已完成
1 期
A Phase I/II Study of MGCD0103 (MG-0103) in Combination With GemcitabineTumorsNCT00372437Mirati Therapeutics Inc.47
终止
2 期
Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's LymphomaHodgkin's LymphomaNCT00358982Mirati Therapeutics Inc.51
终止
2 期
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory DiseaseMyelogenous Leukemia, AcuteMyelodysplastic SyndromesNCT00374296Mirati Therapeutics Inc.35